Scholarlink

<p>Beta-adrenoblockers are one of the groups of drugs that lead to a reduction in mortality from all and cardiovascular causes, reduce the need for hospitalizations, reduce the severity of clinical manifestations of chronic heart failure, and improve the functional status and quality of life of patients. Four INNs from the group of beta-adrenoblockers are given in clinical recommendations: bisoprolol, carvedilol, metoprolol, and nebivolol. Results from clinical trials (MERIT-HF, CIBIS II, COPERNICUS, SENIORS) of the clinical efficacy of metoprolol, bisoprolol, carvedilol, and nebivolol in the therapy of chronic heart failure were comparatively analyzed. These drugs were also evaluated for potential drug interactions. Bisoprolol and metoprolol showed the greatest efficacy in the therapy of chronic heart failure. Amiodarone, verapamil, and diltiazem are among the drugs that are not recommended for use in patients with severe chronic heart failure. This is characteristic of all beta-blockers. Drug interactions between all analyzed beta-blockers and aminophylline and theophylline were noteworthy. The interactions were identified as major (decrease of beta-blocker activity and increase of aminophylline and theophylline activity were registered on the background of joint administration). The largest number of drug interactions was identified for carvedilol. Major interactions of this beta-blocker with beta-adrenomimetics (formoterol, salmeterol), bronchodilators widely used for treatment of obstruction on the background of bronchial asthma and chronic obstructive pulmonary disease, were registered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative Analysis of the Efficacy of Beta-Blockers in the Treatment of Chronic Heart Failure Based on Methods of Attribute Statistics and Drug Interaction Analysis

  • 期刊论文

  • 发表日期：

    2025年4月1日

查看全文
  • O. V. Zhukova,
  • N. L. Shimanovsky

摘要

Beta-adrenoblockers are one of the groups of drugs that lead to a reduction in mortality from all and cardiovascular causes, reduce the need for hospitalizations, reduce the severity of clinical manifestations of chronic heart failure, and improve the functional status and quality of life of patients. Four INNs from the group of beta-adrenoblockers are given in clinical recommendations: bisoprolol, carvedilol, metoprolol, and nebivolol. Results from clinical trials (MERIT-HF, CIBIS II, COPERNICUS, SENIORS) of the clinical efficacy of metoprolol, bisoprolol, carvedilol, and nebivolol in the therapy of chronic heart failure were comparatively analyzed. These drugs were also evaluated for potential drug interactions. Bisoprolol and metoprolol showed the greatest efficacy in the therapy of chronic heart failure. Amiodarone, verapamil, and diltiazem are among the drugs that are not recommended for use in patients with severe chronic heart failure. This is characteristic of all beta-blockers. Drug interactions between all analyzed beta-blockers and aminophylline and theophylline were noteworthy. The interactions were identified as major (decrease of beta-blocker activity and increase of aminophylline and theophylline activity were registered on the background of joint administration). The largest number of drug interactions was identified for carvedilol. Major interactions of this beta-blocker with beta-adrenomimetics (formoterol, salmeterol), bronchodilators widely used for treatment of obstruction on the background of bronchial asthma and chronic obstructive pulmonary disease, were registered.